Paloma Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Paloma Partners’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,858	Closed	-$47K	–	2397
2016 Q4	$47K	Buy	+10,858	New	+$70.2K	﹤0.01%	1931
2016 Q3	–	Sell	-59,558	Closed	-$337K	–	2321
2016 Q2	$337K	Buy	+59,558	New	+$404K	﹤0.01%	1718
2013 Q3	–	Sell	-41,037	Closed	-$384K	–	1323
2013 Q2	$384K	Buy	+41,037	New	+$527K	0.02%	569

Other funds holding CASC

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Paloma Partners's CASC Position: Q1 2017 in Review

Paloma Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2017, closing a stake of 10,858 shares — an estimated $47K sold.

Paloma Partners first reported a position in CASC in Q2 2013 and held it in 3 quarters. The position peaked at $384K in Q2 2013. 78 funds tracked by Wall St. Rank hold CASC as of Q1 2017.

Paloma Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Paloma Partners sold 10,858 Cascadian Therapeutics, Inc. shares in Q1 2017, an estimated $47K.
Paloma Partners first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
Paloma Partners's Cascadian Therapeutics, Inc. position peaked at $384K in Q2 2013.
78 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2017.

Based on Paloma Partners's 13F filing for Q1 2017, filed 15 May 2017.